SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

Strona główna・Stock List・DBV Technologies SA

D
DBV Technologies SA

Closed

3.364 -0.53

Buy Sell

Overview

Share price change

24h

Current

Min

3.35

Max

3.472

Key metrics
By Trading Economics
Income	-2.4M -48M
Profit margin	-1,323.179
Employees	161
EBITDA	-4.1M -46M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-3.55% downside

Dividends
By Dow Jones
Next Earnings	29 lip 2026

Market Stats
By TradingEconomics
Market Cap	-7.7M 1B
Previous open	3.89
Previous close	3.364

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

1.61 / 1.72 Support & Resistance

DBV Technologies SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 maj 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 maj 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 maj 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 maj 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 maj 2026, 16:02 UTC

Earnings

Major Market Movers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 maj 2026, 14:55 UTC

Major Market Movers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 maj 2026, 14:43 UTC

Major Market Movers

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 maj 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 maj 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 maj 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 maj 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 maj 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 maj 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 maj 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 maj 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 maj 2026, 16:24 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 maj 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 maj 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 maj 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 maj 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 maj 2026, 15:20 UTC

Earnings

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 maj 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer Comparison

Price change

DBV Technologies SA Forecast

Price Target

By TipRanks

-3.55% downside

12 Months Forecast

Average 3.26 EUR -3.55%

High 5.5 EUR

Low 1.01 EUR

Based on 2 Wall Street analysts offering 12 month price targets forDBV Technologies SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to DBV Technologies SA - Dist in the past 3 months.

Technical Score

By Trading Central

1.61 / 1.72Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.